EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Surgically Treated pT2aN0M0 (Stage IB) Non-Small Cell Lung Cancer: A 20-Year Single-Center Retrospective Study

Monica Casiraghi iD, Francesco Petrella iD, Claudia Bardoni, Shehab Mohamed iD, Giulia Sedda iD, Juliana Guarize, Antonio Passaro iD, Filippo De Marinis, Patrick Maisonneuve iD, Lorenzo Spaggiari

Journal of Clinical Medicine · 06.03.2023 · 12 (5) · 2081

DOI: 10.3390/jcm12052081 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 06.03.2023. Verfasst von Monica Casiraghi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Ministry of Health with Ricerca Corrente and 5x1000 funds, Italian Ministry of Health with Ricerca Corrente, 5 × 1000 funds.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The suitability of adjuvant therapy (AT) in patients with stage IB non-small cell lung cancer (NSCLC) is still under debate considering the cost–benefit ratio between improvement in survival and side effects. We retrospectively evaluated survival and incidence of recurrence in radically resected stage IB NSCLC, to determine whether AT could significantly improve prognosis.

Methods

Between 1998 and 2020, 4692 consecutive patients underwent lobectomy and systematic lymphadenectomy for NSCLC. Two hundred nineteen patients were pathological T2aN0M0 (>3 and ≤4 cm) NSCLC 8th TNM. None received preoperative or AT. Overall survival (OS), cancer specific survival (CSS) and the cumulative incidence of relapse were plotted and log-rank or Gray’s tests were used to assess the difference in outcome between groups.

Results

The most frequent histology was adenocarcinoma (66.7%). Median OS was 146 months. The 5-, 10-, and 15-year OS rates were 79%, 60%, and 47%, whereas the 5-, 10-, and 15-year CSS were 88%, 85%, and 83%, respectively. OS was significantly related to age (p < 0.001) and cardiovascular comorbidities (p = 0.04), whereas number of LNs removed was an independent prognostic factor of CSS (p = 0.02). Cumulative incidence of relapse at 5-, 10-, and 15-year were 23%, 31%, and 32%, respectively, and significantly related to the number of LNs removed (p = 0.01). Patients with more than 20 LNs removed and clinical stage I had a significantly lower relapse (p = 0.02).

Conclusions

Excellent CSS, up to 83% at 15-year, and relatively low risk of recurrence for stage IB NSCLC (8th TNM) patients suggested that AT for those patients could be reserved only for very selected high-risk cases.

Schlagwörter

Stichwörter der Autor:innen

T2aN0M0non-small cell lung cancerstage IBsurgery

Autor:innen und Institutionen

  • Department of Thoracic Surgery, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy.
  • Department of Oncology and Hemato-Oncology, University of Milan, 20141 Milan, Italy.
  • Division of Oncology, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy.
  • Division of Epidemiology and Biostatistics, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy.

ORCID-Profile: Monica Casiraghi, Francesco Petrella, Shehab Mohamed, Giulia Sedda, Antonio Passaro, Patrick Maisonneuve

Förderung

  • Italian Ministry of Health with Ricerca Corrente and 5x1000 funds
  • Italian Ministry of Health with Ricerca Corrente
  • 5 × 1000 funds

Zitieren

APA

Casiraghi, M., Petrella, F., Bardoni, C., Mohamed, S., Sedda, G., Guarize, J., Passaro, A., De Marinis, F., Maisonneuve, P., & Spaggiari, L. (2023). Surgically Treated pT2aN0M0 (Stage IB) Non-Small Cell Lung Cancer: A 20-Year Single-Center Retrospective Study. Journal of Clinical Medicine, 12(5), 2081. https://doi.org/10.3390/jcm12052081

Vancouver

Casiraghi M, Petrella F, Bardoni C, Mohamed S, Sedda G, Guarize J, et al. Surgically Treated pT2aN0M0 (Stage IB) Non-Small Cell Lung Cancer: A 20-Year Single-Center Retrospective Study. Journal of Clinical Medicine. 2023;12(5):2081. doi:10.3390/jcm12052081

BibTeX
@article{Casiraghi2023,
  author = {Casiraghi, Monica and Petrella, Francesco and Bardoni, Claudia and Mohamed, Shehab and Sedda, Giulia and Guarize, Juliana and Passaro, Antonio and De Marinis, Filippo and Maisonneuve, Patrick and Spaggiari, Lorenzo},
  title = {Surgically Treated pT2aN0M0 (Stage IB) Non-Small Cell Lung Cancer: A 20-Year Single-Center Retrospective Study},
  journal = {Journal of Clinical Medicine},
  year = {2023},
  volume = {12},
  number = {5},
  pages = {2081},
  doi = {10.3390/jcm12052081}
}
Kostenlos starten →